TipRanks
Advertisement
Advertisement

PHRRF Stock Latest News

PharmaTher Secures Exclusive North American Rights to Craft Health’s 3D Pharma Printing Platform
Company AnnouncementsPharmaTher Secures Exclusive North American Rights to Craft Health’s 3D Pharma Printing Platform
2d ago
PharmaTher Taps PD Labs as U.S. Hub for 3D-Printed Personalized Medicines
PremiumCompany Announcements
PharmaTher Taps PD Labs as U.S. Hub for 3D-Printed Personalized Medicines
2M ago
PharmaTher Unveils PERSONALIZ3D Platform to Merge Telehealth and 3D-Printed Personalized Medicines
PremiumCompany Announcements
PharmaTher Unveils PERSONALIZ3D Platform to Merge Telehealth and 3D-Printed Personalized Medicines
2M ago
Source Rock Royalties Declares Monthly Dividend and Grants Incentive RSUs
PremiumCompany Announcements
Source Rock Royalties Declares Monthly Dividend and Grants Incentive RSUs
3M ago
PharmaTher Files U.S. Patent to Bolster Peptide Microneedle Patch Platform
PremiumCompany Announcements
PharmaTher Files U.S. Patent to Bolster Peptide Microneedle Patch Platform
6M ago
PharmaTher Unveils PatchPrint 3D Microneedle Patch Platform and Commercialization Push
PremiumCompany AnnouncementsPharmaTher Unveils PatchPrint 3D Microneedle Patch Platform and Commercialization Push
6M ago
PharmaTher Targets U.S. Peptide Market With Expansion of PharmaPatch Microneedle Platform
Premium
Company Announcements
PharmaTher Targets U.S. Peptide Market With Expansion of PharmaPatch Microneedle Platform
7M ago
PharmaTher Targets Early Entry Into Canada’s Emerging Generic Semaglutide Market
Premium
Company Announcements
PharmaTher Targets Early Entry Into Canada’s Emerging Generic Semaglutide Market
8M ago
PharmaTher Extends Microneedle Patch Platform to GLP-1 Obesity Market
PremiumCompany Announcements
PharmaTher Extends Microneedle Patch Platform to GLP-1 Obesity Market
9M ago
PharmaTher CEO Targets 2026 Asset Monetization After Ketamine ANDA Sale and FDA Win
PremiumCompany Announcements
PharmaTher CEO Targets 2026 Asset Monetization After Ketamine ANDA Sale and FDA Win
9M ago
PharmaTher Sells Ketamine ANDA to Focus on Long-Acting Injectable Program
PremiumCompany Announcements
PharmaTher Sells Ketamine ANDA to Focus on Long-Acting Injectable Program
10M ago
PharmaTher Secures Rights to Long-Acting Ketamine Program for Neuropsychiatric Disorders
PremiumCompany Announcements
PharmaTher Secures Rights to Long-Acting Ketamine Program for Neuropsychiatric Disorders
11M ago
PharmaTher Poised for Growth as FDA Prioritizes Ketamine
PremiumCompany AnnouncementsPharmaTher Poised for Growth as FDA Prioritizes Ketamine
12M ago
PharmaTher Advances Phase 3 FDA Package for Ketamine in Parkinson’s Treatment
Premium
Company Announcements
PharmaTher Advances Phase 3 FDA Package for Ketamine in Parkinson’s Treatment
12M ago
PharmaTher Launches AI Platform to Expand Ketamine Portfolio
Premium
Company Announcements
PharmaTher Launches AI Platform to Expand Ketamine Portfolio
12M ago
PharmaTher Advances Ketamine Program for Parkinson’s Disease Dyskinesia
PremiumCompany Announcements
PharmaTher Advances Ketamine Program for Parkinson’s Disease Dyskinesia
12M ago
Psychedelic: Enveric announces EB-003 manufacturing milestones
PremiumThe Fly
Psychedelic: Enveric announces EB-003 manufacturing milestones
1y ago
ENVB
NRXP
PharmaTher Advances Ketamine Strategy with Strategic Asset Sale
PremiumCompany Announcements
PharmaTher Advances Ketamine Strategy with Strategic Asset Sale
1y ago
PharmaTher provides update on ketamine development, commercial strategy
PremiumThe Fly
PharmaTher provides update on ketamine development, commercial strategy
1y ago
PharmaTher Sells Ketamine ANDA with Potential $25 Million Upside
PremiumCompany AnnouncementsPharmaTher Sells Ketamine ANDA with Potential $25 Million Upside
1y ago
PharmaTher announces sales of ketamine ANDA
Premium
The Fly
PharmaTher announces sales of ketamine ANDA
1y ago
PharmaTher Advances Ketamine Patch for Non-Opioid Pain Relief
Premium
Company Announcements
PharmaTher Advances Ketamine Patch for Non-Opioid Pain Relief
1y ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >